FREE Stock Alerts By Email!
News Alert: Sinobiopharma Inc. (
SNBP) - Zacks Equity Research Initiates
Coverage on Sinobiopharma with Outperform Rating and Six Month Price Target
of $0.80"
(See Full Story Below)
CLICK HERE to Download Zacks Research Report
Sinobiopharma Inc. (OTCBB:
SNBP)
Detailed Quote:
Breaking
SNBP News:
November 19 - Zacks Equity Research Initiates Coverage on Sinobiopharma
Zacks Equity Research has initiated investment research coverage on
Sinobiopharma, Inc. (OTC Bulletin Board:
SNBP) with an Outperform and six
month target price of $0.80. Jiangsu, China-based
SNBP, known domestically
as Dong Ying Pharmaceutical Co. Ltd., is a fully integrated and high growth
company engaged in the R&D, manufacture and distribution of
biopharmaceutical products. The company focuses primarily on the
development of anesthesia-assisted agents as well as antibiotics for
penicillin-allergic patients and cardiovascular-related products related to
high blood pressure (commercial in October 2009). KuTai,
SNBP`s flagship
product is a first-to-market Cisatracurium Besylate injectable that serves
as a low cost skeletal muscle relaxant used during pre-surgical and
surgical procedures. The company holds five patents in Chiral
Pharmaceutical Ingredient Synthesis and Purification, and Molecular
Packaging Formulation (see proprietary technology section) and has the
longer-term ability to expand both the breadth of its product line and
market share through R&D partnerships with Cornell University, Nanjing
University, China Pharmaceutical University, and Nanjing Medical
University.
About Zacks Equity Research
Founded in 1978 in Chicago, Zacks Investment Research, Inc. is one of the
largest independent investment research and consulting firms in the United
States. With 30 years of experience, dedicated to providing clients with
the highest standards of services, Zacks has become an industry leader in
providing institutional and individual investors with the analytical tools
and financial information necessary to the success of their investment
process.
Zacks provides clients with professional services in the area of
investment research, wealth management, and investment consulting. This
information is made available through institutional and non-institutional
product lines and web sites, as well as Zacks` own websites
and ..
Company Overview
Sinobiopharma Inc. is an emerging, fully integrated and highly innovative
biotechnology company engaged in the research and development, manufacture
and marketing of biopharmaceutical products in China, the world`s fastest
growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical
Co. Ltd. in China, the Company`s current therapeutic focus is on
anaesthesia-assisted agents and cardiovascular drugs. Founded in 2004,
Sinobiopharma employs more than 80 people at its corporate office and
production facility in Nantong, China.
Sinobiopharma launched its extremely low-cost, Chinese patented new
formulation of the pre-surgical skeletal muscle relaxant Cisatracurium
Besylate on May 30, 2006. By October 2007, it had captured 80% of the
Chinese market and was in use in more than 200 hospitals.
Anesthetics Product Pipeline
Cisatracurium besylate
Nondepolarizing skeletal muscle relaxant; indicated for inpatients and
outpatients as an adjunct to general anesthesia; facilitates tracheal
intubation, and provides skeletal muscle relaxation during surgery or
mechanical ventilation in the ICU; approved by the
SFDA in 2006.
Rocuronium
Nondepolarizing neuromuscular blocking agent with a rapid to intermediate
onset depending on dose and intermediate duration; indicated for inpatients
and outpatients as an adjunct to general anesthesia to facilitate both
rapid sequence and routine tracheal intubation and to provide skeletal
muscle relaxation during surgery or mechanical ventilation.
Gantacurium chloride
New, investigational, non-depolarizing ultra-short acting neuromuscular
blocker; used as an adjunct to general anesthesia to enable rapid
intubation of patients undergoing surgery.
Cardiovascular Product Pipeline
Eplerenone
Blocker of aldosterone binding at the mineralocorticoid receptor;
indicated for congestive heart failure, post-myocardial infarction
and hypertension.
Perindopril
Non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor;
indicated for stable coronary artery disease hypertension.
Clevidipine butyrate
Dihydropyridine calcium channel blocker; indicated for the reduction of
blood pressure when oral therapy is not feasible or desirable.
Revenue Forecast
Investment Highlights
Leadership of CEO, Dr. Lequn Lee Huang a former manager of the Bayer Co.,
one of the world`s largest pharmaceutical companies
Diverse portfolio of marketed products and robust product pipeline
Proven track record of product development and commercialization
Strong financial management with CFO formerly of JP Morgan Chase and Smith
Kline Beecham
Patented technology for fast, low-cost synthesis of active pharmaceutical
ingredients (API) enhances capability for rapid development of new drugs
Proven R&D partners for collaborative drug discovery and established
relationships with multinationals for outsourced drug development
Nationwide sales and distribution network
Patented technology for rapid low cost drug discovery
Experienced management with international track record
Flagship drug a best seller in China
Robust product pipeline and increasingly diversified portfolio
R&D Strength
Sinobiopharma conducts research and development through Nanjing Su Ji
Biotech Research Development Center and in cooperation with the Medicinal
Chemistry Research Institute, Nanjing University. Both are located at
Nanjing University in Nanjing. The city has emerged as one of China major
biotech research and development centres. Sinobiopharma`s R&D team of 18
specialists (out of a total staff of 80) are highly experienced research
personnel and medical professionals. They have given the Company a strong
intellectual property base with six patents (see table below), primarily in
the area of new methods for synthesizing compounds at lower cost, more
rapidly and/or with greater ease of use. This strong R&D capacity, coupled
with Sinobiopharma`s established links with multinational pharmaceutical
companies makes the Company an attractive partner as a contract research
organization (CRO).
Growth Strategy
Sinobiopharma has a clearly defined strategy to drive short, middle and
long term growth. All drug development will leverage the Company`s patented
technology for fast, low-cost drug synthesis and new technology for
formulation.
In the Short Term, the focus is launching drugs new to the Chinese market.
The Company`s patented synthesis method allows the company to develop new
active pharmaceutical ingredients (API) at lower cost and new formulations
that generally offer greater convenience in application and efficacy with
fewer side effects.
The Middle Term will focus on exporting Active Pharmaceutical Ingredients
and Drug Reformulations developed with the Company`s patented technology
for the global market.
The Long Term will focus on applying the technology platform to
identifying candidate compounds from Traditional Chinese Medicines. Such
compounds have proven their safety and efficacy over thousands of years of
use. Sinobiopharma will accelerate their discovery, synthesis and
formulation for pharmaceutical applications.
Leverage patented technology for fast, low-cost drug synthesis and new
drug formulation
Short-term focus on launching Me-too/Me-better drugs new to the
Chinese market
Medium-term focus on exporting APIs and drug reformulations
Long-term focus on applying the technology platform to identify candidate
compounds from Traditional Chinese Medicines, Me-new
Future Chinese Teva (Israel)
Competitive Advantages
Expanding in fast-growing Chinese healthcare market
Proprietary technology enables low cost, high quality API and innovative
formulations for unstable drugs
Experience with Chinese FDA expedites fast approval of first-to-market
(FTM) drugs
FTM drugs get higher price points and exclusivity
Integrated marketing and distribution support higher profit
Government support includes no-interest loan, tax advantages for five
years, and high-tech cooperation benefits
Sales and Distribution
Nationwide Distribution Network
Sinobiopharma has an established a nationwide sales and marketing network
that distributes its products in 30 provinces and key major cities
throughout China. The Company intends to expand its sales and marketing
infrastructure to meet China`s rapidly growing demand for safer,
lower-cost, higher-efficacy drugs.
Chinese Pharmaceutical Market Growing at Record Levels
Sinobiopharma is expanding in one of the world`s largest and fastest
growing markets. The Chinese pharmaceutical market is among the world`s
largest, ranking ninth in both terms of volume and dollar value, at $9.8
billion in 2005. (
MIDAS Sales Data, IMS Health, March 2006).
It is also one of the world`s fastest growing. From 2001 to 2005 the
Chinese pharmaceutical industry`s compound annual growth rate (
CAGR) was
21%, almost triple the 8%, the global average. The industry is expected to
continue this rapid growth, with IMS Health projecting China to have the
world`s fifth largest market by 2010.
Other Recent
SNBP News:
November 16 - Sinobiopharma has Production Rights to 23 Drugs Listed in
China`s National Essential Drugs List
All Drugs on List to be Covered by Basic Government Insurance That Will
Cover 90 Percent of China`s Population
Sinobiopharma, Inc. (OTCBB:
SNBP) is pleased to announce that 23 generic
drugs for which the Company has production rights are listed in China`s
National Essential Drugs List, which covers pharmaceuticals used to treat
up to 80 percent of the most common diseases in China.
According to the Chinese government`s healthcare reform plan, 90 percent
of China`s citizens will be covered by a universal healthcare system by the
year 2010. Under the plan, drugs on the National Essential Drugs List (the
"List") will be purchased by various levels of government first, then
distributed to medical facilities. All drugs on the List will be covered by
the basic insurance plan supported by the government. The plan also calls
for medical facilities to be upgraded, which includes the construction of
30,000 new hospitals, clinics and care centers across China.
"While Sinobiopharma is primarily focused on the development, production
and distribution of "me-too/me-better" branded new or generic drugs with
high margins, the inclusion of 23 generic drugs for which the Company owns
production rights on the National Essential Drugs List, will enable us to
increase both sales and margins," said Dr. Lequn Lee Huang, Sinobiopharma
President and CEO. "We expect that this new advantage in the marketplace
will also enable the Company to enhance our ability to improve return on
investment for shareholders in 2010."
About Sinobiopharma
Sinobiopharma, Inc. is a fully integrated and highly innovative specialty
biopharmaceutical company engaged in the research and development,
manufacture and marketing of biopharmaceutical products in China, the
world`s fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu)
Pharmaceutical Co., Ltd. in China, the Company`s current therapeutic focus
is on anesthesia-assisted agents and cardiovascular drugs.
Sinobiopharma Inc.
2 Huangpu Road,
Nanjing,Jiangsu Province 210000,
People`s Republic of China
Tel:86.25.8622.8290
Fax:86.25.8320.2848
Website:
www.sinobiopharma.com
OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078,
Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS
REPORT. We are not registered as a securities broker-dealer or an
investment adviser either with the U.S. Securities and Exchange Commission
(the SEC) or with any state securities regulatory authority. We are
neither licensed nor qualified to provide investment advice. OTCPicks.com
makes no recommendation that the purchase of securities of companies
profiled in this web site is suitable or advisable for any person or that
an investment such securities will be profitable. In general, given the
nature of the companies profiled and the lack of an active trading market
for their securities, investing in such securities is highly speculative
and carries a high degree of risk. You are receiving this email because you
have registered on OTCPicks.com or one of our affiliate companies.
To view our full disclaimer go to:
Disclosure: OTCPicks has been compensated five thousand dollars from a
third party for a one week
SNBP advertising and promotional program.
Previously OTCPicks.com has been compensated three thousand dollars by a
third party (WFWS Consulting) for
SNBP advertising and promotional coverage
back in May, 2009.
See OTC Picks's website for full disclaimer. OTC Picks may have received compensation for stock picks.
home
